Drugs company suspected of bribing doctors
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.German prosecutors said yesterday that they suspected the British drugs company GlaxoSmithKline of paying bribes and perks to about 4,000 doctors. Hospital doctors had been given cash sums ranging from €50 to €25,000 (£30 to £15,500) as well as Formula One and 1998 World Cup tickets in France, prosecutors said.
Manfred Wick, Munich's chief prosecutor, said the payments made by Glaxo, which has since merged with SmithKline Beecham, had led to suspicions of bribery and tax evasion.
Mr Wick said a majority of individual cases had been dropped because of the small sums involved. But 100 cases against German doctors and 380 involving SmithKline employees were still being pursued.
The drugs firm, which became Europe's biggest through the merger in 2000, said it was co-operating fully with the German inquiry. It said the accusations related mainly to the period from 1997 to 1999. Since then the company has been restructured.
The allegations, on the same day that its chairman, Sir Richard Sykes, announced he was to step down after a nine-year tenure, mark the latest bad news for the company in the past fortnight.
A survey, by Labour Research, showed that Sir Richard would probably receive a pension payout of £657,000 a year, while staff joining the company could no longer join the group's final salary pension scheme. News of his resignation did not affect the company's share price, which was up 0.1 per cent to £17.20 during afternoon trading on the Stock Exchange.
The company said last night that it had previously offered the principal prosecutor in Munich "active support". In a statement, the company said: "GlaxoSmithKline places tremendous worth on an uncompromising explanation of the course of events.
"According to what we have already discovered, the accusations encompass the time period of 1997 to 1999. The company has been newly restructured through the merger of Glaxo Wellcome and SmithKlineBeecham and many positions have been newly defined and filled; responsibilities have changed."
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments